Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	coumarin 7-hydroxylase activity	CYP2A6 CYP2A13	6.28e-05	3	92	2	GO:0008389
GeneOntologyMolecularFunction	JUN kinase activity	MAPK8 MAPK9	6.28e-05	3	92	2	GO:0004705
GeneOntologyBiologicalProcess	protein localization to tricellular tight junction	LSR MAPK8 MAPK9	3.65e-07	4	94	3	GO:0061833
GeneOntologyBiologicalProcess	vesicle cargo loading	CTAGE9 CTAGE8 CTAGE15 CTAGE4	2.13e-05	36	94	4	GO:0035459
GeneOntologyBiologicalProcess	cellular response to cadmium ion	CYP2A6 CYP2A13 MAPK8 MAPK9	4.36e-05	43	94	4	GO:0071276
GeneOntologyCellularComponent	endoplasmic reticulum exit site	CTAGE9 CTAGE8 CTAGE15 CTAGE4	3.76e-05	42	94	4	GO:0070971
Domain	Cyt_P450_E_grp-I_CYP2A-like	CYP2A6 CYP2A13	1.31e-04	4	88	2	IPR008067
Domain	MAPK_JNK	MAPK8 MAPK9	2.17e-04	5	88	2	IPR008351
Domain	-	IARS2 RARS2	1.17e-03	11	88	2	1.10.730.10
Domain	MAP_kinase_CS	MAPK8 MAPK9	1.40e-03	12	88	2	IPR003527
Domain	MAPK	MAPK8 MAPK9	1.40e-03	12	88	2	PS01351
Domain	KRAB	ZNF567 ZNF562 POGK ZNF566 ZFP1 ZNF561 ZNF850	1.51e-03	358	88	7	PS50805
Domain	KRAB	ZNF567 ZNF562 POGK ZNF566 ZFP1 ZNF561 ZNF850	1.51e-03	358	88	7	PF01352
Domain	KRAB	ZNF567 ZNF562 POGK ZNF566 ZFP1 ZNF561 ZNF850	1.79e-03	369	88	7	SM00349
Domain	KRAB	ZNF567 ZNF562 POGK ZNF566 ZFP1 ZNF561 ZNF850	1.82e-03	370	88	7	IPR001909
Domain	PLipase_C_Pinositol-sp_Y	PLCD3 PLCG1	2.21e-03	15	88	2	IPR001711
Domain	EF-hand_like	PLCD3 PLCG1	2.21e-03	15	88	2	PF09279
Domain	PIPLC_Y_DOMAIN	PLCD3 PLCG1	2.21e-03	15	88	2	PS50008
Domain	PI-PLC_fam	PLCD3 PLCG1	2.21e-03	15	88	2	IPR001192
Domain	PLC_EF-hand-like	PLCD3 PLCG1	2.21e-03	15	88	2	IPR015359
Domain	PI-PLC-Y	PLCD3 PLCG1	2.21e-03	15	88	2	PF00387
Domain	PLCYc	PLCD3 PLCG1	2.21e-03	15	88	2	SM00149
Domain	tRNAsynth_Ia_anticodon-bd	IARS2 RARS2	2.21e-03	15	88	2	IPR009080
Domain	Cyt_P450	CYP2A6 CYP2A13 SRPX2	2.85e-03	60	88	3	IPR001128
Domain	aa-tRNA-synth_I_CS	IARS2 RARS2	3.20e-03	18	88	2	IPR001412
Domain	PI-PLC-X	PLCD3 PLCG1	3.20e-03	18	88	2	PF00388
Domain	PLCXc	PLCD3 PLCG1	3.20e-03	18	88	2	SM00148
Domain	PIPLC_X_DOMAIN	PLCD3 PLCG1	3.56e-03	19	88	2	PS50007
Domain	PLipase_C_PInositol-sp_X_dom	PLCD3 PLCG1	3.56e-03	19	88	2	IPR000909
Domain	AA_TRNA_LIGASE_I	IARS2 RARS2	3.56e-03	19	88	2	PS00178
Pathway	KEGG_MEDICUS_REFERENCE_REGULATION_OF_GF_RTK_RAS_ERK_SIGNALING_PTP	DUSP6 MAPK8 MAPK9	1.43e-04	20	73	3	M47928
Pathway	REACTOME_XENOBIOTICS	CYP2A6 CYP2A13 AHR	2.19e-04	23	73	3	M5372
Pathway	KEGG_MEDICUS_PATHOGEN_HIV_VPR_TAT_TO_TNF_JNK_SIGNALING_PATHWAY	MAPK8 MAPK9	2.62e-04	5	73	2	M47570
Pathway	KEGG_MEDICUS_ENV_FACTOR_NNK_TO_DNA_ADDUCTS	CYP2A6 CYP2A13	2.62e-04	5	73	2	M47808
Pathway	KEGG_MEDICUS_ENV_FACTOR_PARAQUAT_TO_FAS_JNK_SIGNALING_PATHWAY	MAPK8 MAPK9	2.62e-04	5	73	2	M49021
Pathway	KEGG_MEDICUS_PATHOGEN_HTLV_1_TAX_TO_TNF_JNK_SIGNALING_PATHWAY	MAPK8 MAPK9	2.62e-04	5	73	2	M49005
Pathway	REACTOME_XENOBIOTICS	CYP2A6 CYP2A13 AHR	2.82e-04	25	73	3	MM14846
Pathway	KEGG_MEDICUS_VARIANT_MUTATION_CAUSED_ABERRANT_HTT_TO_TNF_JNK_SIGNALING_PATHWAY	MAPK8 MAPK9	3.91e-04	6	73	2	M47680
Pathway	KEGG_MEDICUS_VARIANT_MUTATION_CAUSED_ABERRANT_ABETA_TO_IRE1A_JNK_SIGNALING_PATHWAY	MAPK8 MAPK9	3.91e-04	6	73	2	M47698
Pathway	KEGG_MEDICUS_VARIANT_MUTATION_INACTIVATED_DJ1_TO_FAS_JNK_SIGNALING_PATWHAY	MAPK8 MAPK9	3.91e-04	6	73	2	M47712
Pathway	REACTOME_MAPK_TARGETS_NUCLEAR_EVENTS_MEDIATED_BY_MAP_KINASES	DUSP6 MAPK8 MAPK9	3.98e-04	28	73	3	MM15132
Pathway	WP_CANNABINOID_RECEPTOR_SIGNALING	AHR MAPK8 MAPK9	4.42e-04	29	73	3	M39676
Pathway	REACTOME_MAPK_TARGETS_NUCLEAR_EVENTS_MEDIATED_BY_MAP_KINASES	DUSP6 MAPK8 MAPK9	5.40e-04	31	73	3	M15195
Pathway	PID_NEPHRIN_NEPH1_PATHWAY	PLCG1 MAPK8 MAPK9	5.40e-04	31	73	3	M193
Pathway	KEGG_MEDICUS_REFERENCE_IRE1A_JNK_SIGNALING_PATHWAY	MAPK8 MAPK9	5.46e-04	7	73	2	M47697
Pathway	KEGG_MEDICUS_REFERENCE_FAS_JNK_SIGNALING_PATHWAY	MAPK8 MAPK9	5.46e-04	7	73	2	M47711
Pathway	KEGG_MEDICUS_ENV_FACTOR_METALS_TO_JNK_SIGNALING_PATHWAY	MAPK8 MAPK9	7.26e-04	8	73	2	M47814
Pathway	REACTOME_OXIDATIVE_STRESS_INDUCED_SENESCENCE	EED MAPK8 MAPK9	9.12e-04	37	73	3	MM14899
Pathway	BIOCARTA_DSP_PATHWAY	DUSP6 MAPK8	9.30e-04	9	73	2	M22032
Pathway	BIOCARTA_DSP_PATHWAY	DUSP6 MAPK8	9.30e-04	9	73	2	MM1554
Pathway	REACTOME_SIGNALING_BY_NTRK2_TRKB	PLCG1 BDNF	9.30e-04	9	73	2	MM15583
Pubmed	A critical role for MAP kinases in the control of Ah receptor complex activity.	AHR MAPK8 MAPK9	2.04e-08	3	96	3	15272135
Pubmed	Genetic regulation of coumarin hydroxylase activity in mice. Evidence for single locus control on chromosome.	CYP2A6 CYP2A13 AHR	4.05e-07	6	96	3	447675
Pubmed	JNK-mediated phosphorylation of DLK suppresses its ubiquitination to promote neuronal apoptosis.	USP9X MAPK8 MAPK9	7.08e-07	7	96	3	23979718
Pubmed	JNK1/2-dependent phosphorylation of angulin-1/LSR is required for the exclusive localization of angulin-1/LSR and tricellulin at tricellular contacts in EpH4 epithelial sheet.	LSR MAPK8 MAPK9	1.13e-06	8	96	3	24889144
Pubmed	C-Jun N-terminal kinase (JNK) isoforms play differing roles in otitis media.	MAPK8 MAPK9	7.54e-06	2	96	2	25311344
Pubmed	Genetic inhibition or activation of JNK1/2 protects the myocardium from ischemia-reperfusion-induced cell death in vivo.	MAPK8 MAPK9	7.54e-06	2	96	2	16043490
Pubmed	Combined Activities of JNK1 and JNK2 in Hepatocytes Protect Against Toxic Liver Injury.	MAPK8 MAPK9	7.54e-06	2	96	2	26708719
Pubmed	Functional in vivo interactions between JNK1 and JNK2 isoforms in obesity and insulin resistance.	MAPK8 MAPK9	7.54e-06	2	96	2	16818881
Pubmed	Suppression of inflammatory cytokine production by carbon monoxide involves the JNK pathway and AP-1.	MAPK8 MAPK9	7.54e-06	2	96	2	12857751
Pubmed	JNK1, but not JNK2, is required in two mechanistically distinct models of inflammatory arthritis.	MAPK8 MAPK9	7.54e-06	2	96	2	21839715
Pubmed	Suppressed hepatocyte proliferation via a ROS-HNE-P21 pathway is associated with nicotine- and cotinine-enhanced alcoholic fatty liver in mice.	CYP2A6 CYP2A13	7.54e-06	2	96	2	30876690
Pubmed	CYP2A5 induction and hepatocellular stress: an adaptive response to perturbations of heme homeostasis.	CYP2A6 CYP2A13	7.54e-06	2	96	2	21395539
Pubmed	Prevention of steatosis by hepatic JNK1.	MAPK8 MAPK9	7.54e-06	2	96	2	19945406
Pubmed	Hypothermia attenuates ischemia/reperfusion-induced endothelial cell apoptosis via alterations in apoptotic pathways and JNK signaling.	MAPK8 MAPK9	7.54e-06	2	96	2	19596001
Pubmed	Species differences in coumarin metabolism: a molecular modelling evaluation of CYP2A interactions.	CYP2A6 CYP2A13	7.54e-06	2	96	2	12162851
Pubmed	Molecular characterization of the murine Coh locus: an amino acid difference at position 117 confers high and low coumarin 7-hydroxylase activity in P450coh.	CYP2A6 CYP2A13	7.54e-06	2	96	2	1302041
Pubmed	Structural alteration of mouse P450coh by mutation of glycine-207 to proline: spin equilibrium, enzyme kinetics, and heat sensitivity.	CYP2A6 CYP2A13	7.54e-06	2	96	2	8395817
Pubmed	Increased JNK in males compared with females in a rodent model of abdominal aortic aneurysm.	MAPK8 MAPK9	7.54e-06	2	96	2	22316675
Pubmed	c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis.	MAPK8 MAPK9	7.54e-06	2	96	2	11435459
Pubmed	Absence of cytochrome P450 2A5 enhances alcohol-induced liver injury in mice.	CYP2A6 CYP2A13	7.54e-06	2	96	2	25804444
Pubmed	Effect of pyrazole, cobalt and phenobarbital on mouse liver cytochrome P-450 2a-4/5 (Cyp2a-4/5) expression.	CYP2A6 CYP2A13	7.54e-06	2	96	2	1520280
Pubmed	Role of CYP2A13 in the bioactivation and lung tumorigenicity of the tobacco-specific lung procarcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone: in vivo studies using a CYP2A13-humanized mouse model.	CYP2A6 CYP2A13	7.54e-06	2	96	2	23917075
Pubmed	The JNKs differentially regulate RNA polymerase III transcription by coordinately modulating the expression of all TFIIIB subunits.	MAPK8 MAPK9	7.54e-06	2	96	2	19620725
Pubmed	Genomic Landscape of Experimental Bladder Cancer in Rodents and Its Application to Human Bladder Cancer: Gene Amplification and Potential Overexpression of Cyp2a5/CYP2A6 Are Associated with the Invasive Phenotype.	CYP2A6 CYP2A13	7.54e-06	2	96	2	27902773
Pubmed	JNK inhibition reduces apoptosis and neovascularization in a murine model of age-related macular degeneration.	MAPK8 MAPK9	7.54e-06	2	96	2	23341606
Pubmed	Defective neural tube morphogenesis and altered apoptosis in the absence of both JNK1 and JNK2.	MAPK8 MAPK9	7.54e-06	2	96	2	10559486
Pubmed	Inhibition of arachidonate 5-lipoxygenase triggers prostate cancer cell death through rapid activation of c-Jun N-terminal kinase.	MAPK8 ALOX5	7.54e-06	2	96	2	12859962
Pubmed	JNK regulates muscle remodeling via myostatin/SMAD inhibition.	MAPK8 MAPK9	7.54e-06	2	96	2	30072727
Pubmed	Inhibition of JNK reduces G2/M transit independent of p53, leading to endoreduplication, decreased proliferation, and apoptosis in breast cancer cells.	MAPK8 MAPK9	7.54e-06	2	96	2	14724588
Pubmed	Circadian Regulation of Hepatic Cytochrome P450 2a5 by Peroxisome Proliferator-Activated Receptor γ.	CYP2A6 CYP2A13	7.54e-06	2	96	2	30154104
Pubmed	Coordination of JNK1 and JNK2 is critical for GADD45alpha induction and its mediated cell apoptosis in arsenite responses.	MAPK8 MAPK9	7.54e-06	2	96	2	16973625
Pubmed	c-Jun N-terminal kinase 2 suppresses pancreatic cancer growth and invasion and is opposed by c-Jun N-terminal kinase 1.	MAPK8 MAPK9	7.54e-06	2	96	2	33526844
Pubmed	Mechanism-based inhibition of cytochrome P450 (CYP)2A6 by chalepensin in recombinant systems, in human liver microsomes and in mice in vivo.	CYP2A6 CYP2A13	7.54e-06	2	96	2	21418183
Pubmed	Decreased expression of phosphorylated JNK in breast infiltrating ductal carcinoma is associated with a better overall survival.	MAPK8 MAPK9	7.54e-06	2	96	2	16381010
Pubmed	Protective role of c-Jun N-terminal kinase 2 in acetaminophen-induced liver injury.	MAPK8 MAPK9	7.54e-06	2	96	2	18586006
Pubmed	JNK/SAPK Signaling Is Essential for Efficient Reprogramming of Human Fibroblasts to Induced Pluripotent Stem Cells.	MAPK8 MAPK9	7.54e-06	2	96	2	26867034
Pubmed	Role of CYP2A5 in the clearance of nicotine and cotinine: insights from studies on a Cyp2a5-null mouse model.	CYP2A6 CYP2A13	7.54e-06	2	96	2	19923441
Pubmed	Effects of lipopolysaccharide-stimulated inflammation and pyrazole-mediated hepatocellular injury on mouse hepatic Cyp2a5 expression.	CYP2A6 CYP2A13	7.54e-06	2	96	2	12499123
Pubmed	Function and regulation of the Cyp2a5/CYP2A6 genes in response to toxic insults in the liver.	CYP2A6 CYP2A13	7.54e-06	2	96	2	22497566
Pubmed	Jun N-terminal kinase 1 regulates epithelial-to-mesenchymal transition induced by TGF-beta1.	MAPK8 MAPK9	7.54e-06	2	96	2	18334556
Pubmed	A pathogenic role for c-Jun amino-terminal kinase signaling in renal fibrosis and tubular cell apoptosis.	MAPK8 MAPK9	7.54e-06	2	96	2	17202416
Pubmed	The role of JNK in the development of hepatocellular carcinoma.	MAPK8 MAPK9	7.54e-06	2	96	2	21406557
Pubmed	JNK1/2 regulates ER-mitochondrial Ca2+ cross-talk during IL-1β-mediated cell death in RINm5F and human primary β-cells.	MAPK8 MAPK9	7.54e-06	2	96	2	23615449
Pubmed	Signal transduction by the JNK group of MAP kinases.	MAPK8 MAPK9	7.54e-06	2	96	2	11057897
Pubmed	Silencing Jnk1 and Jnk2 accelerates basal lipolysis and promotes fatty acid re-esterification in mouse adipocytes.	MAPK8 MAPK9	7.54e-06	2	96	2	18528680
Pubmed	The role of CYP2A5 in liver injury and fibrosis: chemical-specific difference.	CYP2A6 CYP2A13	7.54e-06	2	96	2	26363552
Pubmed	Mouse liver P450Coh: genetic regulation of the pyrazole-inducible enzyme and comparison with other P450 isoenzymes.	CYP2A6 CYP2A13	7.54e-06	2	96	2	2712571
Pubmed	JNK-dependent Stat3 phosphorylation contributes to Akt activation in response to arsenic exposure.	MAPK8 MAPK9	7.54e-06	2	96	2	22696236
Pubmed	Ablation of the spindle assembly checkpoint by a compound targeting Mps1.	MAPK8 MAPK9	7.54e-06	2	96	2	16113653
Pubmed	c-Jun N-terminal kinase 1 is deleterious to the function and survival of murine pancreatic islets.	MAPK8 MAPK9	7.54e-06	2	96	2	18853132
Pubmed	Ultrafine particles from diesel engines induce vascular oxidative stress via JNK activation.	MAPK8 MAPK9	7.54e-06	2	96	2	19154785
Pubmed	Role of the MAPK/cJun NH2-terminal kinase signaling pathway in starvation-induced autophagy.	MAPK8 MAPK9	7.54e-06	2	96	2	29950132
Pubmed	Specific role of JNK in the maintenance of the tumor-initiating capacity of A549 human non-small cell lung cancer cells.	MAPK8 MAPK9	7.54e-06	2	96	2	23912840
Pubmed	Evaluation of inhibition selectivity for human cytochrome P450 2A enzymes.	CYP2A6 CYP2A13	7.54e-06	2	96	2	22696418
Pubmed	JNK is required for maintaining the tumor-initiating cell-like properties of acquired chemoresistant human cancer cells.	MAPK8 MAPK9	7.54e-06	2	96	2	26235742
Pubmed	C-Jun NH(2)-terminal kinase mediates proliferation and tumor growth of human prostate carcinoma.	MAPK8 MAPK9	7.54e-06	2	96	2	12538493
Pubmed	Inhibition of Jun NH2-terminal kinases suppresses the growth of experimental head and neck squamous cell carcinoma.	MAPK8 MAPK9	7.54e-06	2	96	2	17908987
Pubmed	c-Jun N-terminal kinase 1/2 activation by tumor necrosis factor-alpha induces insulin resistance in human visceral but not subcutaneous adipocytes: reversal by liver X receptor agonists.	MAPK8 MAPK9	7.54e-06	2	96	2	19567513
Pubmed	Defective antiviral CD8 T-cell response and viral clearance in the absence of c-Jun N-terminal kinases.	MAPK8 MAPK9	7.54e-06	2	96	2	24673683
Pubmed	[Sodium butyrate do not induce the program of premature senescence in transformants with JNK1,2 knockout].	MAPK8 MAPK9	7.54e-06	2	96	2	19140343
Pubmed	Modulation of the response of prostate cancer cell lines to cisplatin treatment using small interfering RNA.	MAPK8 MAPK9	7.54e-06	2	96	2	23900581
Pubmed	Inhibition of c-Jun N-terminal kinase attenuates low shear stress-induced atherogenesis in apolipoprotein E-deficient mice.	MAPK8 MAPK9	7.54e-06	2	96	2	21629969
Pubmed	c-Jun N-terminal protein kinase 1 (JNK1), but not JNK2, is essential for tumor necrosis factor alpha-induced c-Jun kinase activation and apoptosis.	MAPK8 MAPK9	7.54e-06	2	96	2	15572687
Pubmed	Hepatotoxicity mediated by pyrazole (cytochrome P450 2E1) plus tumor necrosis factor alpha treatment occurs in c-Jun N-terminal kinase 2-/- but not in c-Jun N-terminal kinase 1-/- mice.	MAPK8 MAPK9	7.54e-06	2	96	2	21748763
Pubmed	Purinergic (ATP) signaling stimulates JNK1 but not JNK2 MAPK in osteoblast-like cells: contribution of intracellular Ca2+ release, stress activated and L-voltage-dependent calcium influx, PKC and Src kinases.	MAPK8 MAPK9	7.54e-06	2	96	2	18625195
Pubmed	Tumor necrosis factor-induced toxic liver injury results from JNK2-dependent activation of caspase-8 and the mitochondrial death pathway.	MAPK8 MAPK9	7.54e-06	2	96	2	16571730
Pubmed	Nicotine enhances alcoholic fatty liver in mice: Role of CYP2A5.	CYP2A6 CYP2A13	7.54e-06	2	96	2	30222954
Pubmed	Up-regulation of CYP2A5 expression by porphyrinogenic agents in mouse liver.	CYP2A6 CYP2A13	7.54e-06	2	96	2	7543189
Pubmed	c-Jun N-terminal kinase 2 promotes enterocyte survival and goblet cell differentiation in the inflamed intestine.	MAPK8 MAPK9	7.54e-06	2	96	2	28098247
Pubmed	c-Jun N-terminal kinase is upregulated in patients with hypospadias.	MAPK8 MAPK9	7.54e-06	2	96	2	23273084
Pubmed	Soluble Adenylyl Cyclase Is Required for Retinal Ganglion Cell and Photoreceptor Differentiation.	ADCY10 ATOH7	7.54e-06	2	96	2	27679853
Pubmed	An initial phase of JNK activation inhibits cell death early in the endoplasmic reticulum stress response.	MAPK8 MAPK9	7.54e-06	2	96	2	27122189
Pubmed	Characterization and regulation of sex-specific mouse steroid hydroxylase genes.	CYP2A6 CYP2A13	7.54e-06	2	96	2	2372744
Pubmed	JNK2 up-regulates hypoxia-inducible factors and contributes to hypoxia-induced erythropoiesis and pulmonary hypertension.	MAPK8 MAPK9	7.54e-06	2	96	2	29118187
Pubmed	c-Jun N-terminal kinase activity is required for efficient respiratory syncytial virus production.	MAPK8 MAPK9	7.54e-06	2	96	2	28062184
Pubmed	c-Jun NH(2)-terminal kinase (JNK)1 and JNK2 have distinct roles in CD8(+) T cell activation.	MAPK8 MAPK9	7.54e-06	2	96	2	11927626
Pubmed	c-Jun NH(2)-terminal kinase (JNK)1 and JNK2 signaling pathways have divergent roles in CD8(+) T cell-mediated antiviral immunity.	MAPK8 MAPK9	7.54e-06	2	96	2	11927625
Pubmed	Metabolic effects of CYP2A6 and CYP2A13 on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced gene mutation--a mammalian cell-based mutagenesis approach.	CYP2A6 CYP2A13	7.54e-06	2	96	2	21473878
Pubmed	Efficient keratinocyte differentiation strictly depends on JNK-induced soluble factors in fibroblasts.	MAPK8 MAPK9	7.54e-06	2	96	2	24335928
Pubmed	Inhibition of cell proliferation and cell cycle progression by specific inhibition of basal JNK activity: evidence that mitotic Bcl-2 phosphorylation is JNK-independent.	MAPK8 MAPK9	7.54e-06	2	96	2	14704147
Pubmed	The CYP2A gene subfamily: species differences, regulation, catalytic activities and role in chemical carcinogenesis.	CYP2A6 CYP2A13	7.54e-06	2	96	2	7581481
Pubmed	RIOK3-mediated phosphorylation of MDA5 interferes with its assembly and attenuates the innate immune response.	IFIH1 RIOK3	7.54e-06	2	96	2	25865883
Pubmed	Differential roles of JNK in ConA/GalN and ConA-induced liver injury in mice.	MAPK8 MAPK9	7.54e-06	2	96	2	18772342
Pubmed	c-Jun NH2-terminal kinase-2 mediates osmotic stress-induced tight junction disruption in the intestinal epithelium.	MAPK8 MAPK9	7.54e-06	2	96	2	20595622
Pubmed	Interstrain differences in the expression and activity of Cyp2a5 in the mouse liver.	CYP2A6 CYP2A13	7.54e-06	2	96	2	28298240
Pubmed	c-Jun NH2-terminal kinase is required for lineage-specific differentiation but not stem cell self-renewal.	MAPK8 MAPK9	7.54e-06	2	96	2	20065035
Pubmed	Genetic polymorphisms for a phenobarbital-inducible cytochrome P-450 map to the Coh locus in mice.	CYP2A6 CYP2A13	7.54e-06	2	96	2	6309775
Pubmed	Inhibited neurogenesis in JNK1-deficient embryonic stem cells.	MAPK8 MAPK9	7.54e-06	2	96	2	16314504
Pubmed	JNK1 and 2 play a negative role in reprogramming to pluripotent stem cells by suppressing Klf4 activity.	MAPK8 MAPK9	7.54e-06	2	96	2	24211391
Pubmed	Protective role of c-Jun N-terminal kinase-2 (JNK2) in ibuprofen-induced acute liver injury.	MAPK8 MAPK9	7.54e-06	2	96	2	30264435
Pubmed	Role of CYP2A5 in the bioactivation of the lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in mice.	CYP2A6 CYP2A13	7.54e-06	2	96	2	22262919
Pubmed	Modulation of cytochrome P450 2A5 activity by lipopolysaccharide: low-dose effects and non-monotonic dose-response relationship.	CYP2A6 CYP2A13	7.54e-06	2	96	2	25635819
Pubmed	Caffeic acid attenuates the decrease of cortical BDNF transcript IV mRNA induced by swim stress in wild-type but not in 5-lipoxygenase-deficient mice.	ALOX5 BDNF	7.54e-06	2	96	2	18305891
Pubmed	Genetic variation between mice in their metabolism of coumarin and its derivatives.	CYP2A6 CYP2A13	7.54e-06	2	96	2	566237
Pubmed	c-Jun N-terminal kinase 2 (JNK2) antagonizes the signaling of differentiation by JNK1 in human myeloid leukemia cells resistant to vitamin D.	MAPK8 MAPK9	7.54e-06	2	96	2	19339050
Pubmed	Identification and characterization of a 44 kDa protein that binds specifically to the 3'-untranslated region of CYP2a5 mRNA: inducibility, subcellular distribution and possible role in mRNA stabilization.	CYP2A6 CYP2A13	7.54e-06	2	96	2	8611142
Pubmed	Deletion of JNK Enhances Senescence in Joint Tissues and Increases the Severity of Age-Related Osteoarthritis in Mice.	MAPK8 MAPK9	7.54e-06	2	96	2	32418287
Pubmed	The contribution of common UGT2B10 and CYP2A6 alleles to variation in nicotine glucuronidation among European Americans.	CYP2A6 UGT2B10	7.54e-06	2	96	2	24192532
Pubmed	Genetic deletion of JNK1 and JNK2 aggravates the DSS-induced colitis in mice.	MAPK8 MAPK9	7.54e-06	2	96	2	17365404
Pubmed	Coumarin toxicity in different strains of mice.	CYP2A6 CYP2A13	7.54e-06	2	96	2	665441
Cytoband	19q13.12	ZNF567 LSR ZNF566 ZNF850	1.66e-05	72	96	4	19q13.12
Cytoband	7q35	CTAGE8 CTAGE15 CTAGE4	2.15e-04	55	96	3	7q35
Cytoband	Ensembl 112 genes in cytogenetic band chr7q35	CTAGE8 CTAGE15 CTAGE4	3.69e-04	66	96	3	chr7q35
GeneFamily	CTAGE family	CTAGE9 CTAGE8 CTAGE15 CTAGE4	2.72e-07	15	70	4	907
GeneFamily	Mitogen-activated protein kinases	MAPK8 MAPK9	1.12e-03	13	70	2	651
GeneFamily	Aminoacyl tRNA synthetases, Class I	IARS2 RARS2	2.42e-03	19	70	2	131
GeneFamily	Phospholipases\|C2 domain containing phospholipases	PLCD3 PLCG1	2.42e-03	19	70	2	832
ToppCell	TCGA-Thryoid-Primary_Tumor-Thyroid_Papillary_Carcinoma-Classical\|TCGA-Thryoid / Sample_Type by Project: Shred V9	PLCD3 LSR UNC5B DUSP6 AHR FAXC ELF3	1.99e-07	194	95	7	b46c54802b8d1e0a0a17f9ed8e82eaf5e7f4849d
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Immune\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	BLK RIN3 DOCK8 CNTRL MYO1F BIN2 ALOX5	2.06e-07	195	95	7	7b6c69df943842b566a596e30bb50dbe80dccc83
ToppCell	renal_cortex_nuclei-Hypertensive_with+without-CKD-Immune-Myeloid-Monocytic-Non-classical_Monocyte\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	NEDD9 RIN3 DUSP6 MYO1F BIN2 ALOX5	2.52e-06	181	95	6	8657d35cd3dff6c89d0fde67d7e7e81e1d6c8884
ToppCell	renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell_/_Pericyte\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	LDB3 DOCK8 DAAM2 IRAG1 BDNF RYR2	3.04e-06	187	95	6	48bfdb3504c3fefe5db3abac4b790c369680ab4e
ToppCell	renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell_/_Pericyte-\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	LDB3 DOCK8 DAAM2 IRAG1 BDNF RYR2	3.04e-06	187	95	6	958402fcc78f4c7a7d13d659d776f3817137975f
ToppCell	renal_medulla_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell-Myofibroblast-\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	LDB3 ANKS1B IRAG1 LPAR1 BDNF RYR2	3.33e-06	190	95	6	2e88e366d377d74deb53a4ea870973ce5c6532e8
ToppCell	renal_medulla_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell-Myofibroblast\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	LDB3 ANKS1B IRAG1 LPAR1 BDNF RYR2	3.33e-06	190	95	6	0028f886c789ba238c031eae5d96acaed4af8c25
ToppCell	E15.5-Epithelial-alveolar_epithelial_cell-type_I_pneumocyte\|E15.5 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase	NEDD9 LSR LMO7 SESN3 ELF3 EIF3H	3.44e-06	191	95	6	402c341b00f98e8215458766b3c219fff8dcb447
ToppCell	3'-Parenchyma_lung-Epithelial-Epithelial_transtional-epithelial_cell_of_lung-Transitional_Club-AT2\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	CYP2A6 LSR LMO7 AHR ELF3 ATL2	3.76e-06	194	95	6	5b29c843186c2394f5bec3b1d5ae284a0d931d85
ToppCell	3'-Parenchyma_lung-Epithelial-Epithelial_transtional\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	CYP2A6 LSR LMO7 AHR ELF3 ATL2	3.76e-06	194	95	6	ebcf6c6d0eb20a5d422becf5a730089230c8ba9a
ToppCell	3'-Parenchyma_lung-Epithelial-Epithelial_transtional-epithelial_cell_of_lung\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	CYP2A6 LSR LMO7 AHR ELF3 ATL2	3.76e-06	194	95	6	8c6e5ba27a988e0cd6b8c25cb9a30a0da2b1f7f9
ToppCell	3'-Parenchyma_lung-Epithelial-Epithelial_transtional-epithelial_cell_of_lung-Transitional_Club-AT2-Transitional_Club-AT2_L.0.4.1.0\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	CYP2A6 LSR LMO7 AHR ELF3 ATL2	3.76e-06	194	95	6	6e78e3046c5b172af92a84e25f982377a0aaac58
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Immune\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	BLK RIN3 DOCK8 MYO1F BIN2 ALOX5	3.87e-06	195	95	6	2d485373bfd9bb4bb9236bf0b31d03e132c8018f
ToppCell	Children_(3_yrs)-Immune-monocyte-D032\|Children_(3_yrs) / Lineage, Cell type, age group and donor	RIN3 DOCK8 DUSP6 MYO1F DAAM2 DYSF	3.87e-06	195	95	6	81a28289eda1a8a1a31b7357106f64ac5000e172
ToppCell	Fetal_29-31_weeks-Immune-monocyte-D062\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	RIN3 DOCK8 DUSP6 MYO1F BIN2 ALOX5	4.11e-06	197	95	6	8b9a88fb671d5c2b25d291c851e2b8a478f2610c
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Immune\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	BLK RIN3 DOCK8 MYO1F BIN2 ALOX5	4.11e-06	197	95	6	61ef3f417767c3f5296a26399da63e3e4f58faf8
ToppCell	COVID-19-lung-Macrophage_VCANhi_FCN1hi\|COVID-19 / Disease (COVID-19 only), tissue and cell type	RIN3 DOCK8 MYO1F BIN2 DYSF ALOX5	4.23e-06	198	95	6	ea34096bee852a7e996f097fa279381afa8f86ff
ToppCell	distal-1-Epithelial-Club\|1 / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	CYP2A6 LSR CYP2A13 HOOK1 LMO7 ELF3	4.35e-06	199	95	6	8f0a72a95d0310ef2324c6975495c294b5a47cc8
ToppCell	distal-Epithelial-Club-1\|distal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	CYP2A6 LSR CYP2A13 HOOK1 LMO7 ELF3	4.35e-06	199	95	6	685cefbe6ff5db8b578e50b5849524ac2f347d0c
ToppCell	Parenchymal-10x3prime_v2-Stromal-Myofibroblastic-Muscle_perivascular_immune_recruiting\|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations	IFIH1 ZFP1 IRAG1 MAPK8 ATL2 BDNF	4.48e-06	200	95	6	a372ef3f9e6ff6e3c3376d6e10182977c5067788
ToppCell	Smart-start-Cell-Wel_seq-Non-neoplastic-Glial-Neuronal-Oligodendrocyte-Oligodendrocyte-F\|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	LDB3 DNAH17 ANKS1B DAAM2 DYSF LPAR1	4.48e-06	200	95	6	829978708463a7459fe1041bd90196775bc4b531
ToppCell	Bac-SEP-Lymphocyte-T_NK-dnT\|Bac-SEP / Disease, Lineage and Cell Type	ZHX3 ZNF566 ANKS1B TIMELESS XKR6	2.39e-05	160	95	5	f5ca49801c981b903a85a64b21ece6b59fe91cbc
ToppCell	renal_medulla_nuclei-Adult_normal_reference-Immune-Myeloid-Monocytic-Non-classical_Monocyte\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	RIN3 MYO1F BIN2 ALOX5 RSPH10B	3.47e-05	173	95	5	0a0127bcb1d7b2b6125faef576dd843055095528
ToppCell	Control-Epithelial-Club\|Epithelial / Disease state, Lineage and Cell class	CYP2A6 CYP2A13 AHR FAXC ATL2	4.78e-05	185	95	5	6814b3c94c7558443c038a227b5c8563d2cfeac4
ToppCell	COVID-19-Fibroblasts-Pericytes\|COVID-19 / group, cell type (main and fine annotations)	LDB3 CDH20 DAAM2 IRAG1 RYR2	4.78e-05	185	95	5	4905adaeeffd353e089578e5ea614437dbe794e6
ToppCell	COVID-19-lung-B_cells\|COVID-19 / Disease (COVID-19 only), tissue and cell type	BLK DOCK8 CNTRL SESN3 XKR6	4.78e-05	185	95	5	e8f1ad580f19705b5ca1d7d8867b2125f4891684
ToppCell	kidney_cells-Adult_normal_reference-Mesenchymal-glomerular_mesenchymal_cell-Mesangial_Cell-mesangial_typical\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	LMO7 UNC5B ADAM9 DAAM2 IRAG1	5.03e-05	187	95	5	d591a3c216997663ab77710fed0d230ffc37e41a
ToppCell	kidney_cells-Adult_normal_reference-Mesenchymal-glomerular_mesenchymal_cell-Mesangial_Cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	LMO7 UNC5B ADAM9 DAAM2 IRAG1	5.03e-05	187	95	5	d1dc8c9a2c2cd10c640257161a75e7730ec5bb41
ToppCell	kidney_cells-Adult_normal_reference-Mesenchymal-glomerular_mesenchymal_cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	LMO7 UNC5B ADAM9 DAAM2 IRAG1	5.03e-05	187	95	5	ac8e092b37e042975e2ee057d3f7c6821e58e8b5
ToppCell	facs-Brain_Non-Myeloid-Hippocampus-24m-Neuronal-neuron\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SRPX2 FAXC CHD3 BDNF RYR2	5.03e-05	187	95	5	e04a84989d624378141042768383b9c846901f2d
ToppCell	facs-Brain_Non-Myeloid-Hippocampus-24m-Neuronal-nan\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SRPX2 FAXC CHD3 BDNF RYR2	5.03e-05	187	95	5	24cc03c748e15f7ef0e6509ca5a6ca583fb9c573
ToppCell	facs-Brain_Non-Myeloid-Hippocampus-24m-Neuronal\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SRPX2 FAXC CHD3 BDNF RYR2	5.03e-05	187	95	5	2f153b203fe79f206319603cf94d3a03ab49a05d
ToppCell	PCW_10-12-Hematologic_ErythroMegGranulo\|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung	KRT1 DOCK8 MYO1F BIN2 ALOX5	5.16e-05	188	95	5	adf9011ba8e3c6418fb68bf5c44b2e3b0ec7dafe
ToppCell	renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Myocytic_interstitial_cell\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	LDB3 DOCK8 DAAM2 IRAG1 RYR2	5.29e-05	189	95	5	fac5c291a9a87418bb0878c3d624829bdbf1f428
ToppCell	LV-08._Macrophage\|World / Chamber and Cluster_Paper	RIN3 DOCK8 MYO1F DAAM2 ALOX5	5.56e-05	191	95	5	e7a0bc46ba9ba772636a583f3387748418e18832
ToppCell	RV-08._Macrophage\|World / Chamber and Cluster_Paper	RIN3 DOCK8 MYO1F DAAM2 ALOX5	5.70e-05	192	95	5	a1b5dc5beb97a23729b97b54fb4574d10d8fbfb3
ToppCell	PCW_10-12-Hematologic_Myeloid-Hem_Myeloid_monocytic-im_monocyte_(14)\|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung	DOCK8 MYO1F BIN2 DYSF ALOX5	5.70e-05	192	95	5	d44f46352bac414b45cc749f7cbdc3a159bd7ae8
ToppCell	LV-08._Macrophage\|LV / Chamber and Cluster_Paper	RIN3 DOCK8 MYO1F DAAM2 ALOX5	5.70e-05	192	95	5	7be12d580aaf2f2f1562203fcad3a44639b8c5a6
ToppCell	E15.5-Epithelial-alveolar_epithelial_cell\|E15.5 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase	NEDD9 LSR LMO7 SESN3 EIF3H	5.70e-05	192	95	5	567f4355a01aae1f2eafc16fe86d1538a62030ab
ToppCell	Children_(3_yrs)-Immune-monocyte-D046\|Children_(3_yrs) / Lineage, Cell type, age group and donor	AMPD3 RIN3 DOCK8 MYO1F BIN2	5.84e-05	193	95	5	58e1930a1d80ad3729ab9604ac8ebf7308232a3d
ToppCell	RV-08._Macrophage\|RV / Chamber and Cluster_Paper	RIN3 DOCK8 MYO1F DAAM2 ALOX5	5.84e-05	193	95	5	12bf98a280f87e4d8f0c6887dfc855da72e47ac1
ToppCell	severe-low-quality_cells\|severe / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	RSPH10B2 SESN3 N4BP2L2 PLCG1 CTAGE4	5.84e-05	193	95	5	9337bc93e3904c7fc7c93c328518bcd6453b1e8c
ToppCell	droplet-Bladder-nan-3m-Epithelial-bladder_urothelial_cell\|Bladder / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	LSR LMO7 DUSP6 AHR ELF3	5.84e-05	193	95	5	ee91a796d0f6d4cee7a93a525689e716fdceeda5
ToppCell	CV-Severe-5\|CV / Virus stimulation, Condition and Cluster	LSR HOOK1 RPS15 AHR SESN3	5.84e-05	193	95	5	d87fcd4553b6198c3128685b73ffd1b1ae88fbb5
ToppCell	3'-Broncho-tracheal-Epithelial-Epithelial_transtional\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	CYP2A6 LSR LMO7 ELF3 ATL2	5.99e-05	194	95	5	db06ae2dba45640da329a4d0d94973ac9dda7729
ToppCell	LA-08._Macrophage\|World / Chamber and Cluster_Paper	RIN3 DOCK8 MYO1F DAAM2 ALOX5	5.99e-05	194	95	5	c1805572bcc11b1cd29083329d7b5911489fb758
ToppCell	3'-Broncho-tracheal-Epithelial-Epithelial_transtional-epithelial_cell_of_lung-Transitional_Club-AT2-Transitional_Club-AT2_L.0.4.1.0\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	CYP2A6 LSR LMO7 ELF3 ATL2	5.99e-05	194	95	5	d3f5cd6c40354bfe86348bb0e82697a939759625
ToppCell	3'-Broncho-tracheal-Epithelial-Epithelial_transtional-epithelial_cell_of_lung-Transitional_Club-AT2\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	CYP2A6 LSR LMO7 ELF3 ATL2	5.99e-05	194	95	5	d4f4036b650a27312283fa8851f3975595cc2d3f
ToppCell	3'-Broncho-tracheal-Epithelial-Epithelial_transtional-epithelial_cell_of_lung\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	CYP2A6 LSR LMO7 ELF3 ATL2	5.99e-05	194	95	5	4974c208e6ee37a51cd95a61d48b26c5de416992
ToppCell	renal_medulla_nuclei-Adult_normal_reference-Immune\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	RIN3 DOCK8 MYO1F BIN2 ALOX5	5.99e-05	194	95	5	0866ab6792cee274a71991d5c37a37f574ff446e
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Immune-Myeloid-Monocytic\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	RIN3 DOCK8 MYO1F BIN2 ALOX5	5.99e-05	194	95	5	badefcec2af86cbcd97305f4843e84db0f3ebc66
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Immune-Myeloid-Monocytic-Non-classical_Monocyte\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	RIN3 DOCK8 MYO1F BIN2 ALOX5	6.14e-05	195	95	5	1d58585557bf8e9ce4d514e128d3a902b526331d
ToppCell	normal_Lung-Epithelial_cells-Club\|normal_Lung / Location, Cell class and cell subclass	CYP2A6 LSR CYP2A13 LMO7 ELF3	6.14e-05	195	95	5	b46544ad5af04f4dbc2643637caa3d2d50d922ae
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Immune-Myeloid-Monocytic-Non-classical_Monocyte\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	RIN3 DOCK8 MYO1F BIN2 ALOX5	6.14e-05	195	95	5	10ce1b6961f10372d1f65388cbf3626a5fcd6840
ToppCell	LA-08._Macrophage\|LA / Chamber and Cluster_Paper	RIN3 DOCK8 MYO1F DAAM2 ALOX5	6.14e-05	195	95	5	5e1d5bdb8874091f5a2b1d0a8cc9008165718a97
ToppCell	TCGA-Thryoid-Primary_Tumor\|TCGA-Thryoid / Sample_Type by Project: Shred V9	PLCD3 UNC5B DUSP6 FAXC DYSF	6.14e-05	195	95	5	7cdee2ae90edf15e4cbcf70797b8caf1f037b0ef
ToppCell	TCGA-Thryoid-Primary_Tumor-Thyroid_Papillary_Carcinoma\|TCGA-Thryoid / Sample_Type by Project: Shred V9	PLCD3 UNC5B DUSP6 FAXC DYSF	6.14e-05	195	95	5	b61b8c931bd0ca3678486653ae1d7e9915c696c7
ToppCell	wk_20-22-Epithelial-Proximal_epithelial-Club\|wk_20-22 / Celltypes from embryonic and fetal-stage human lung	CYP2A6 LSR CYP2A13 LMO7 ELF3	6.29e-05	196	95	5	4e4c632db73b1340d80bf40a7657cb4821084d3c
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Immune-Myeloid\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	RIN3 DOCK8 MYO1F BIN2 ALOX5	6.29e-05	196	95	5	4370473693d2dd4a8c451a4c477eb79baa33ae12
ToppCell	Fetal_29-31_weeks-Immune-monocyte\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	RIN3 DOCK8 MYO1F BIN2 ALOX5	6.44e-05	197	95	5	48a8169a4d33c6a68d66bcd936861c75cb4b60ef
ToppCell	COVID-19-lung-Macrophage_VCANhi_FCN1hi\|lung / Disease (COVID-19 only), tissue and cell type	DOCK8 MYO1F BIN2 DYSF ALOX5	6.44e-05	197	95	5	a0f8a992282a6d64890f5574c7c9741fcb38dadd
ToppCell	renal_cortex_nuclei-Hypertensive_with+without-CKD-Immune\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	RIN3 DOCK8 MYO1F BIN2 ALOX5	6.44e-05	197	95	5	0523aec9713ae21e6b879aa98e07fa2576610d5f
ToppCell	ASK452-Epithelial-Type_1\|ASK452 / Donor, Lineage and Cell class of Lung cells from Dropseq	LMO7 SLC25A15 AHR ELF3 BDNF	6.44e-05	197	95	5	dc0a6dca4af6b216357b06f67203274f8b2a8bb0
ToppCell	10x_3'_v3-blood_(10x_3'_v3)\|10x_3'_v3 / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	KRT1 MYO1F RIOK3 BIN2 DYSF	6.44e-05	197	95	5	2d3547107c88c7443fc6425742694e13368a71f5
ToppCell	healthy_donor-Lymphocytic-T_cell-CD4+_Naive_T_cell\|healthy_donor / Disease condition, Lineage, Cell class and subclass	HOOK1 LMO7 SESN3 CHD3 PLCG1	6.44e-05	197	95	5	cf72160f03105876641fa6fdc7405e339eb084c7
ToppCell	Children_(3_yrs)-Immune\|Children_(3_yrs) / Lineage, Cell type, age group and donor	RIN3 DOCK8 MYO1F BIN2 ALOX5	6.44e-05	197	95	5	f18807124b91310fcd84238484a80ecdba684679
ToppCell	5'-Airway_Nasal-Epithelial-Epithelial_transtional-secretory-nasal_mucosa_goblet_cell-Goblet_(nasal)-Goblet_(nasal)_L.0.2.2.0\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	CYP2A6 CYP2A13 LMO7 ELF3 HYDIN	6.44e-05	197	95	5	5c4cee914baf7cb43e9cb99cc9e3ae823856dc15
ToppCell	BL\|World / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)	DOCK8 MYO1F BIN2 DYSF ALOX5	6.44e-05	197	95	5	1acf0191fa0a25cd20bfd9ea7bf727a1555986a1
ToppCell	COVID-19_Severe-Classical_Monocyte\|World / disease group, cell group and cell class	ADAM9 DUSP6 AHR KIAA1958 DYSF	6.44e-05	197	95	5	344801997b89bd81d8d5c3c872934de523233a8d
ToppCell	367C-Fibroblasts-Fibroblast-B_(Myofibroblast)-\|Fibroblasts / Donor, Lineage, Cell class and subclass (all cells)	SRPX2 LMO7 UNC5B DAAM2 CHD3	6.60e-05	198	95	5	c55608633f66e3d434c5d81324efb07c5120d2c2
ToppCell	LPS_anti-TNF-Epithelial_alveolar-AT_1-2_Progenitor-Progenitor_AT1-AT2\|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type	NEDD9 LSR HOOK1 LMO7 ELF3	6.60e-05	198	95	5	50852713c017217c79777c95857097103bcf2fbe
ToppCell	Control_saline-Epithelial_airway\|Control_saline / Treatment groups by lineage, cell group, cell type	TTC21A ELF3 CCDC180 HYDIN RSPH10B	6.60e-05	198	95	5	e6863238e022ecfb6a8e3f4b7661b376e92c5d8f
ToppCell	Immune\|World / Lineage, Cell type, age group and donor	RIN3 DOCK8 MYO1F BIN2 ALOX5	6.60e-05	198	95	5	65681b54d13c6997bd90a1c2a12314a80e964fe3
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Mesenchymal\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	LDB3 SRPX2 DAAM2 IRAG1 LPAR1	6.60e-05	198	95	5	79576525a10ed3e3a9d1608077cd16ecda23376f
ToppCell	Fetal_29-31_weeks-Immune\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	RIN3 DOCK8 MYO1F BIN2 ALOX5	6.60e-05	198	95	5	5dff131356b8c22743bd27b2b21f86ee6e4a0a0d
ToppCell	Adult-Immune\|Adult / Lineage, Cell type, age group and donor	RIN3 DOCK8 MYO1F BIN2 ALOX5	6.60e-05	198	95	5	9bfd7b88aa646eaf5eddb15cf985c7ca910cb35e
ToppCell	367C-Fibroblasts-Fibroblast-B_(Myofibroblast)\|Fibroblasts / Donor, Lineage, Cell class and subclass (all cells)	SRPX2 LMO7 UNC5B DAAM2 CHD3	6.60e-05	198	95	5	3e5459038fc6ed95f529eb4d1dc5113e16c19012
ToppCell	Control_saline-Epithelial_airway-airway_epithelial\|Control_saline / Treatment groups by lineage, cell group, cell type	TTC21A ELF3 CCDC180 HYDIN RSPH10B	6.60e-05	198	95	5	e7aa42e5fbd42c68f50cda4a8f3aa464c862c007
ToppCell	Tracheal-NucSeq-Immune_Myeloid-Monocytic-Monocyte_CD16\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	RIN3 DOCK8 MYO1F BIN2 ALOX5	6.60e-05	198	95	5	0b928a829844f49f4d47e88908af192cb919011f
ToppCell	LPS_only-Epithelial_alveolar\|LPS_only / Treatment groups by lineage, cell group, cell type	NEDD9 LSR HOOK1 LMO7 ELF3	6.60e-05	198	95	5	655df75b9692d815c7f6910275e1f684ac63bf62
ToppCell	COVID-19_Severe-Classical_Monocyte\|COVID-19_Severe / disease group, cell group and cell class	DUSP6 MYO1F AHR DYSF ALOX5	6.60e-05	198	95	5	b88c4c0ed1abf0a28dbe05b04b9bee1073855ba8
ToppCell	Immune-monocyte\|World / Lineage, Cell type, age group and donor	RIN3 DOCK8 MYO1F BIN2 ALOX5	6.60e-05	198	95	5	d3622da252fd580f1dc5c7478a8e23df5ec083cf
ToppCell	proximal-Epithelial-Club\|proximal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	CYP2A6 LSR LMO7 ELF3 ATL2	6.75e-05	199	95	5	99d23c0373f1ae5267bb3e51c5c88c8f52559ae4
ToppCell	PBMC-Mild-Myeloid-Classical_Monocyte-Classical_Monocyte-cMono_3\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	ADAM9 DUSP6 AHR DYSF ALOX5	6.75e-05	199	95	5	9314eb9a89407738626a0384884454b5f9031ee7
ToppCell	Transverse-(5)_Dendritic_cell-(51)_cDC1\|Transverse / shred on region, Cell_type, and subtype	CTAGE9 SRPX2 PPY KIAA1958 DYSF	6.75e-05	199	95	5	52dd1c4cd372f8ee515307a9200e357bb2145888
ToppCell	LPS_only-Epithelial_alveolar-AT_1-2_Progenitor\|LPS_only / Treatment groups by lineage, cell group, cell type	NEDD9 LSR HOOK1 LMO7 ELF3	6.75e-05	199	95	5	3a0af1a13b1760f4213d87d0958dbe3bf3b9a42b
ToppCell	10x_5'_v1-Non-neoplastic-Glial-Neuronal-Oligodendrocyte-Oligodendrocyte\|10x_5'_v1 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	LDB3 DNAH17 ANKS1B DAAM2 LPAR1	6.75e-05	199	95	5	5d2e85e40b6b52b1809e680b952913d77215b3d0
ToppCell	Smart-start-Cell-Wel_seq-Non-neoplastic-Myeloid-TAM-MG-TAM-MG_aging_sig-F\|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	NEDD9 RIN3 DOCK8 DUSP6 ALOX5	6.75e-05	199	95	5	b0a906586e58009f5ed9272fc29ba28e49c85ee6
ToppCell	Sepsis-Bac-SEP-Lymphocyte-T/NK-dn_T\|Bac-SEP / Disease, condition lineage and cell class	ZHX3 ZNF566 ANKS1B TIMELESS XKR6	6.75e-05	199	95	5	4150a479b80596accf679b37aa9b0ac15cc132b2
ToppCell	10x_5'_v1-Non-neoplastic-Glial-Neuronal-Oligodendrocyte\|10x_5'_v1 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	LDB3 DNAH17 ANKS1B DAAM2 LPAR1	6.75e-05	199	95	5	9dd4b17fb8c70ab9e126b23b72600463f3db832d
ToppCell	LPS_only-Epithelial_alveolar-AT_1-2_Progenitor-Progenitor_AT1-AT2\|LPS_only / Treatment groups by lineage, cell group, cell type	NEDD9 LSR HOOK1 LMO7 ELF3	6.75e-05	199	95	5	0447f8f53389fe7c6ddc04a97d86e74122ea16f4
ToppCell	distal-3-Epithelial-Club\|3 / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	CYP2A6 LSR LMO7 ELF3 ATL2	6.75e-05	199	95	5	1a0c3506df2438f5be40a8ea72effe5f8ebd35c4
ToppCell	LPS_only-Epithelial_alveolar-AT_1-2_Progenitor-AT2_Progenitor\|LPS_only / Treatment groups by lineage, cell group, cell type	NEDD9 LSR HOOK1 LMO7 ELF3	6.75e-05	199	95	5	7b21447bb39cdba37539a12cb475f463010fc23f
ToppCell	wk_08-11-Epithelial-Airway_epithelial_progenitor\|wk_08-11 / Celltypes from embryonic and fetal-stage human lung	NEDD9 LSR HOOK1 LMO7 ELF3	6.75e-05	199	95	5	af664e0d41a889a75dbf6cf0d50acd26f5ab3a3a
ToppCell	proximal-Epithelial-Club-3\|proximal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	CYP2A6 LSR LMO7 ELF3 ATL2	6.75e-05	199	95	5	e8b3b003b581aa001c23440a03d80da9560129b3
ToppCell	10x_5'_v1-Non-neoplastic-Glial-Neuronal-Oligodendrocyte-Oligodendrocyte-Z\|10x_5'_v1 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	LDB3 DNAH17 ANKS1B DAAM2 LPAR1	6.75e-05	199	95	5	6fb5f931e6217142de38c1fffc011e63bda4772b
ToppCell	distal-Epithelial-Club\|distal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	CYP2A6 LSR HOOK1 LMO7 ELF3	6.75e-05	199	95	5	c63ccce1285352927fd8c4f7374ec5fff8d70cec
ToppCell	proximal-3-Epithelial-Club\|3 / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	CYP2A6 LSR LMO7 ELF3 ATL2	6.75e-05	199	95	5	77dc850032746339557c844cfc1f93eb27210f22
ToppCell	Parenchymal-NucSeq-Immune_Myeloid-Monocytic-Monocyte_CD16\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	RIN3 DOCK8 MYO1F BIN2 ALOX5	6.75e-05	199	95	5	ac866ae110967c5867ff4601939b79861d43df54
ToppCell	10x_5'_v1-Non-neoplastic-Glial-Neuronal\|10x_5'_v1 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	LDB3 DNAH17 ANKS1B DAAM2 LPAR1	6.75e-05	199	95	5	1bb5797e8e0552bf9b44bf4c958d1aa6dbe6c756
Drug	N'-nitrosoanatabine	CYP2A6 CYP2A13 UGT2B10	2.72e-07	4	94	3	ctd:C032978
Drug	N'-nitrosoanabasine	CYP2A6 CYP2A13 UGT2B10	1.35e-06	6	94	3	ctd:C010257
Drug	2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole	KRT1 AHR MAPK8 MAPK9	1.55e-06	21	94	4	ctd:C425784
Drug	acenaphthene	CYP2A6 CYP2A13 AHR	2.36e-06	7	94	3	ctd:C042552
Drug	dinitrophenyl-bovine serum albumin	PLCG1 MAPK8 MAPK9	1.46e-05	12	94	3	ctd:C034638
Drug	Hydroxytacrine maleate (R,S) [118909-22-1]; Down 200; 12.2uM; PC3; HT_HG-U133A	AMPD3 RIN3 VPS13D HOOK1 UNC5B CPT1B RYR2	1.60e-05	194	94	7	6651_DN
Drug	Tadjakonine [11087-94-8]; Down 200; 7.4uM; MCF7; HT_HG-U133A	NEDD9 ZHX3 CNTRL TIMELESS CHD3 PLCG1 CPT1B	1.66e-05	195	94	7	2820_DN
Drug	propargyl ether	CYP2A6 CYP2A13	1.69e-05	2	94	2	ctd:C531209
Drug	Hempa	CYP2A6 CYP2A13	1.69e-05	2	94	2	ctd:D006492
Drug	AC1L1IJ1	PPY ALOX5	1.69e-05	2	94	2	CID000004600
Drug	nicotine imine	CYP2A6 CYP2A13	1.69e-05	2	94	2	ctd:C034629
Drug	alpha-nicotyrine	CYP2A6 CYP2A13	1.69e-05	2	94	2	ctd:C008615
Drug	N-nitrosoguvacoline	CYP2A6 CYP2A13	1.69e-05	2	94	2	ctd:C036676
Drug	Hydroflumethiazide [135-09-1]; Up 200; 12uM; MCF7; HT_HG-U133A	HOOK1 CNTRL DUSP6 MYO1F MAPK8 ATL2 RYR2	1.71e-05	196	94	7	1687_UP
Drug	Phenethicillin potassium salt [132-93-4]; Down 200; 10uM; MCF7; HT_HG-U133A	ZHX3 AMPD3 VPS13D DNAH17 CPT1B MAPK8 DYSF	1.77e-05	197	94	7	6105_DN
Drug	Skatole	CYP2A6 CYP2A13 AHR	1.89e-05	13	94	3	ctd:D012862
Drug	N'-nitrosonornicotine	CYP2A6 CYP2A13 UGT2B10	2.99e-05	15	94	3	ctd:C008655
Drug	puag-haad	AHR MAPK8 MAPK9	2.99e-05	15	94	3	ctd:C034912
Drug	AC1L1B3Z	KRT1 PPY MAPK8 MAPK9	3.57e-05	45	94	4	CID000001273
Drug	N-glyceryl-2-hexyl-3-keto-capramide	KRT1 MAPK9	5.05e-05	3	94	2	CID011645877
Drug	benzothiazol-2-ylacetonitrile	MAPK8 MAPK9	5.05e-05	3	94	2	CID000342465
Drug	CGC 11093	MAPK8 MAPK9	5.05e-05	3	94	2	ctd:C515676
Drug	2'-methoxyacetophenone	CYP2A6 CYP2A13	5.05e-05	3	94	2	CID000068481
Drug	3-nonenal	MAPK8 MAPK9 ALOX5	5.32e-05	18	94	3	CID005283336
Drug	Docosahexaenoic Acids	AHR CPT1B MAPK8 MAPK9 ALOX5 BDNF	5.55e-05	161	94	6	ctd:D004281
Drug	Thr-Gly	TIMELESS MAPK8 MAPK9	6.29e-05	19	94	3	CID006427013
Disease	cotinine measurement, cigarettes per day measurement	CYP2A6 UGT2B10	9.00e-06	2	89	2	EFO_0006525, EFO_0007813
Disease	Tobacco Dependence	CYP2A6 AHR BDNF	9.43e-06	14	89	3	C0040332
Disease	Nicotine Dependence	CYP2A6 AHR BDNF	9.43e-06	14	89	3	C0028043
Disease	Nicotine Use Disorder	CYP2A6 AHR BDNF	9.43e-06	14	89	3	C0376384
Disease	ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 2	LDB3 RYR2	8.94e-05	5	89	2	C1832931
Disease	Hereditary Diffuse Gastric Cancer	CYP2A6 RPS15 AHR MAPK8 ALOX5 BDNF	2.65e-04	293	89	6	C1708349
Disease	Stomach Neoplasms	CYP2A6 RPS15 AHR MAPK8 ALOX5 BDNF	2.85e-04	297	89	6	C0038356
Disease	serum alanine aminotransferase measurement	BLK CYP2A6 CDH20 PPY EFCAB13 EDEM2 N4BP2L2 XKR6 ALOX5 BDNF	2.90e-04	869	89	10	EFO_0004735
Disease	Malignant neoplasm of stomach	CYP2A6 RPS15 AHR MAPK8 ALOX5 BDNF	3.01e-04	300	89	6	C0024623
Disease	nephronophthisis (implicated_via_orthology)	TTC21A CNTRL	3.19e-04	9	89	2	DOID:12712 (implicated_via_orthology)
Disease	coffee consumption measurement, tea consumption measurement	CYP2A6 AHR BDNF	3.21e-04	44	89	3	EFO_0006781, EFO_0010091
Disease	1-methylxanthine measurement	AMPD3 AHR	4.86e-04	11	89	2	EFO_0021174
Disease	Macrocephaly	CHD8 CHD3	4.86e-04	11	89	2	C0221355
Disease	Prostatic Neoplasms	CYP2A6 ADAM9 AHR SESN3 CHD3 EIF3H LPAR1 ALOX5	5.52e-04	616	89	8	C0033578
Disease	Malignant neoplasm of prostate	CYP2A6 ADAM9 AHR SESN3 CHD3 EIF3H LPAR1 ALOX5	5.52e-04	616	89	8	C0376358
Disease	TOBACCO ADDICTION, SUSCEPTIBILITY TO (finding)	CYP2A6 BDNF	5.82e-04	12	89	2	C1861063
Disease	Trigeminal Neuralgia	MAPK8 MAPK9	5.82e-04	12	89	2	C0040997
Disease	Secondary Trigeminal Neuralgia	MAPK8 MAPK9	5.82e-04	12	89	2	C0393787
Disease	Trigeminal Neuralgia, Idiopathic	MAPK8 MAPK9	5.82e-04	12	89	2	C0393786
Disease	coffee consumption, cups of coffee per day measurement	AHR BDNF	1.05e-03	16	89	2	EFO_0004330, EFO_0006782
Disease	Tachycardia	AHR RYR2	1.33e-03	18	89	2	C0039231
Disease	Tachyarrhythmia	AHR RYR2	1.33e-03	18	89	2	C0080203
Disease	osteoarthritis, knee	AMPD3 POGK XKR6 BDNF	1.36e-03	158	89	4	EFO_0004616
Disease	emphysema pattern measurement	CYP2A6 RIN3	1.49e-03	19	89	2	EFO_0005850
Disease	Cannabis use, age at onset	CDH20 RYR2	1.49e-03	19	89	2	EFO_0004847, EFO_0007585
Disease	caffeine metabolite measurement	CYP2A6 AHR	1.49e-03	19	89	2	EFO_0007872
Disease	Lung Injury	AHR ELF3	1.82e-03	21	89	2	C0273115
Disease	Chronic Lung Injury	AHR ELF3	1.82e-03	21	89	2	C2350344
Disease	Allodynia	MAPK8 MAPK9 ALOX5	2.12e-03	84	89	3	C0458247
Disease	Mechanical Allodynia	MAPK8 MAPK9 ALOX5	2.12e-03	84	89	3	C2936719
Disease	Hyperalgesia, Secondary	MAPK8 MAPK9 ALOX5	2.12e-03	84	89	3	C0751212
Disease	Hyperalgesia, Primary	MAPK8 MAPK9 ALOX5	2.12e-03	84	89	3	C0751211
Disease	Hyperalgesia, Thermal	MAPK8 MAPK9 ALOX5	2.12e-03	84	89	3	C0751214
Disease	Tactile Allodynia	MAPK8 MAPK9 ALOX5	2.12e-03	84	89	3	C0751213
Disease	Hyperalgesia	MAPK8 MAPK9 ALOX5	2.12e-03	84	89	3	C0020429
Disease	cotinine measurement	CYP2A6 UGT2B10	2.18e-03	23	89	2	EFO_0007813
Disease	Autism Spectrum Disorders	CHD8 BDNF RYR2	2.19e-03	85	89	3	C1510586
Disease	coffee consumption measurement	CYP2A6 AHR HYDIN BDNF	2.27e-03	182	89	4	EFO_0006781
Disease	Reperfusion Injury	MAPK8 MAPK9 ALOX5	2.50e-03	89	89	3	C0035126
Disease	Colitis	AHR ALOX5	2.58e-03	25	89	2	C0009319
Disease	atopic dermatitis (is_implicated_in)	DOCK8 BDNF	2.79e-03	26	89	2	DOID:3310 (is_implicated_in)
Disease	Sezary Syndrome	CHD3 PLCG1	3.01e-03	27	89	2	C0036920

Protein segments in the cluster

Peptide	Gene	Start	Entry
LLAAMMQQDESIYLY	AHR	456	P35869
YYMHEDILQNRMALD	ERVPABLB-1	371	P60509
RQMIQQYEMYCKDSR	CHD8	896	Q9HCK8
RLMKELNQMQYEYTE	CNTRL	2121	Q7Z7A1
DEMSQDIVKYNTYMR	EIF3H	251	O15372
EEYKNYLDAANMSMR	BDNF	111	P23560
IMTEFYQENEMKLYR	CTAGE4	386	Q8IX94
IMTEFYQENEMKLYR	CTAGE8	386	P0CG41
IMTEFYQENEMKLYR	CTAGE9	386	A4FU28
IMTEFYQENEMKLYR	CTAGE15	386	A4D2H0
MKYKNLMARALYDNV	NEDD9	1	Q14511
TEQMYNSLMKISERY	CYP2A6	51	P11509
YALQVKPQRLMAAMY	EFL1	971	Q7Z2Z2
NSNMTYEKLSRAMRY	ELF3	321	P78545
LLGRNKEINYFMYTM	ADCY10	486	Q96PN6
YRLINEEAMVMNYAL	CCDC180	301	Q9P1Z9
YREMSKLNHNLYEVM	BIN2	221	Q9UBW5
YMYANIMVLNNLRRE	AMPD3	561	Q01432
YMPIKNTNQDIYREM	PPIL4	401	Q8WUA2
MLAQESYPKKRNYTM	ANKS1B	421	Q7Z6G8
REQQRTLYSMSYMNK	RSPH10B	541	P0C881
REQQRTLYSMSYMNK	RSPH10B2	541	B2RC85
YYIDRINSMAAMQSL	DAAM2	101	Q86T65
KMETYLRMADLPYQN	FAXC	121	Q5TGI0
MELDHERMSYLLYQM	MAPK9	121	P45984
LYSAETLREMAQMYQ	LDB3	201	O75112
VRLLMAMAVMLYYSN	MFSD9	291	Q8NBP5
NRYMYVMDTRPKLNA	MTMR6	231	Q9Y217
LQEQADILYMLYTMK	PHKA1	776	P46020
MNPIIYSYRDKEMSA	LPAR1	306	Q92633
LMAMFLEYNKAIRNY	EDEM2	276	Q9BV94
EVMMQYVENLKRTYE	IRAG1	626	Q9Y6F6
LKNMQDMVEDYRNKY	KRT1	256	P04264
MELDHERMSYLLYQM	MAPK8	121	P45983
YYENFLEDKALMIAM	NEK8	66	Q86SG6
MQDYNKDDMSYRRIS	LMO7	286	Q8WWI1
MQSSLEQLYSKYDEM	POLG2	421	Q9UHN1
NSKRMMNAIKESYDY	EED	266	O75530
EQQKALYREVMRMNY	POGK	66	Q9P215
YDNEIVMMNHVYKER	MAST1	171	Q9Y2H9
MAQYAADLRRYINML	PPY	46	P01298
IYILNMAQDYAAMKA	HYDIN	2261	Q4G0P3
TEQMYNSLMKISERY	CYP2A13	51	Q16696
EMLMDLMYRIAKSYQ	DOCK8	1621	Q8NF50
LTYQKYDEMMELLRC	DNAH17	621	Q9UFH2
ALMNMDREAKEYYEV	CDH20	226	Q9HBT6
VMYRNYQRKNDMDEP	CHD3	576	Q12873
LYDYTAMNDRDLQML	BLK	66	P51451
EAVYNNIMRHYLMQK	IFIH1	451	Q9BYX4
LSKYETLQMALSYIM	ATOH7	76	Q8N100
LDFMLRYMYNKDSQS	ATL2	111	Q8NHH9
REEMILLANYLDSMY	ADAM9	236	Q13443
LLANYLDSMYIMLNI	ADAM9	241	Q13443
EKEMLSNLYMTLYDE	EFCAB13	146	Q8IY85
AMEERYKMYLEKARN	HOOK1	601	Q9UJC3
AYLMQKLNLSMNDAY	DUSP6	306	Q16828
LSSYATARLMMNNEY	RYR2	1711	Q92736
CYMYQARDLAAMDKD	DYSF	1156	O75923
MVNSNYYVMDLVLIK	CPT1B	251	Q92523
SQQDDSMRVLYYMEK	LSR	396	Q86X29
SMRVLYYMEKELANF	LSR	401	Q86X29
QDYKVYSLEMMARQT	RIN3	621	Q8TB24
MKELRAYQQSEAYKM	HMG20B	131	Q9P0W2
IDRMDKYNFDTMIYV	RARS2	331	Q5T160
VAENLATYMESMRLY	USP9X	616	Q93008
MMTKVRENNYTYEFD	TRMT5	261	Q32P41
FDYLRKEMTQNIYQM	TMEM126B	61	Q8IUX1
EMYAIYQQRRMEKIN	SAMD7	101	Q7Z3H4
NYSKAMENLFINRFM	ALOX5	181	P09917
DMYVIDQYMLHLLQD	IARS2	751	Q9NSE4
IYYASKDMRDNNMLR	MROH2B	56	Q7Z745
AYEYSRKLMMNQLEA	SLC25A15	286	Q9Y619
NFRKAYNYIRIMVME	GTF3C3	681	Q9Y5Q9
EMKEAYYQTLHLMRQ	RIOK3	381	O14730
LDMSYEQLMQLYSAR	RPS15	26	P62841
TNYYEMMLTDRKEAA	TIMELESS	416	Q9UNS1
YRDVMLENYMNLASV	ZNF561	66	Q8N587
AQKTLYMDVMLENYC	ZNF567	26	Q8N184
ILYMDVMLENYSNLL	ZFP1	31	Q6P2D0
TQKYLYRDVMLENYM	ZNF562	61	Q6V9R5
YRDVMLENYMNLASV	ZNF562	66	Q6V9R5
MYEYADVNMLRLLET	XKR6	281	Q5GH73
DPSNRYYKMQISMLQ	SRPX2	351	O60687
LRMVNVDMNDMYAYL	PLCD3	211	Q8N3E9
DEKFRMVYNLTYNTM	SESN3	376	P58005
LYRSLMYSAQKTMDL	PLCG1	216	P19174
YDMNLREMENYEKIY	THOC7	71	Q6I9Y2
SCYMEAREKMANIYL	TTC21A	691	Q8NDW8
RMLAQKLSMDRYLNY	UNC5B	881	Q8IZJ1
YRDVMLENYSNLVSM	ZNF566	31	Q969W8
FMERVKNMLYVLYFD	UGT2B10	206	P36537
DMLRYYMRDSQAAKD	SNX32	291	Q86XE0
NRELLQDYYMTHKML	ZHX3	846	Q9H4I2
IFENSMDKMYRNLYK	SPATA6	461	Q9NWH7
AAQKDLYRDVMMENY	ZNF850	26	A8MQ14
TKMYERYSLSFMDLQ	VPS13D	811	Q5THJ4
YLNMRTLQEHADLMY	KIAA1958	566	Q8N8K9
IYALTDNMYRNMLID	MYO1F	86	O00160
KKIAQMLDRYEYQMS	N4BP2L2	526	Q92802